Business Wire·Oct 27, 2026
InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026.
InfuSystem's fundamental profile reflects a cost-led profitability reset rather than a growth story: gross margin has expanded roughly 850 basis points since 2024Q2 (49.5% to 58.0%) on a COGS line held near $15–16M, swinging operating income from -$845K to $4.2M, while revenue growth simultaneously slid from 10.7% in…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.15+15.4% vs $0.13 | $37M+0.0% vs $37M |
Q3 2026 Aug 4, 2026 | $0.15+42.9% vs $0.10 | $37M+1.6% vs $36M |
Q2 2026 May 7, 2026 | $0.05+25.0% vs $0.04 | $34M-1.9% vs $34M |
Q1 2026 Feb 24, 2026 | $0.10+42.9% vs $0.07 | $36M-1.2% vs $37M |
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026.
InfuSystem Holdings, Inc. (INFU) Discusses Business Overview and Growth Strategy with Focus on Patient-First Approach Transcript
Guardant Health (NASDAQ: GH - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Earnings and Valuation This table compares Guardant Health and
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Host Investor Webcast on September 24, 2026.
Benchmark INFU against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for InfuSystem Holdings, Inc. (INFU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.69 | $276.29M | 30.56 | 6.36% | 6.54% | 15.77% | — | |
| $12.56 | $236.41M | -15.95 | 1.46% | -14.26% | -8.64% | 8.35% | |
| $24.28 | $1.67B | 16.06 | 7.08% | 5.58% | 20.22% | — | |
| $8.76 | $164.38M | 35.77 | 18.78% | 4.66% | 3.6% | — | |
| $37.34 | $1.7B | 38.85 | 6.53% | 3.59% | 3.5% | — | |
| $3.31 | $482.47M | -25.15 | 19.99% | -6.32% | -8.29% | — |
InfuSystem Holdings, Inc. (INFU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
InfuSystem Holdings, Inc. (INFU) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Aug 4, 2026·SEC
Jul 28, 2026·SEC
Get notified when INFU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
InfuSystem Holdings, Inc. (INFU) stock FAQ — growth, dividends, profitability & financials explained
InfuSystem Holdings, Inc. (INFU) reported $144.4M in revenue over the trailing twelve months. Revenue was $143.4M in fiscal year 2025.
InfuSystem Holdings, Inc. (INFU) grew revenue by 2.4% over the trailing twelve months, compared with the twelve months before.
Yes. InfuSystem Holdings, Inc. (INFU) earned $9.4M in net income over the trailing twelve months (a 6.5% net margin).
InfuSystem Holdings, Inc. (INFU) had a return on equity (ROE) of 15.8% over the trailing twelve months. That is above the market's typical 10-15%.
InfuSystem Holdings, Inc. (INFU) generated $19.8M in free cash flow over the trailing twelve months.
